An early clinical trial of 5-ALA sonodynamic therapy in recurrent high-grade glioma

Overview of attention for article published in Science Translational Medicine, November 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet
blogs: 1 blog

twitter: 6 X users
bluesky: 3 Bluesky users

Readers on

mendeley: 14 Mendeley

So far, Altmetric has seen 3 Bluesky posts from 3 Bluesky users, with an upper bound of 1,149 followers.

Sonodynamic therapy using focused ultrasound and 5-ALA appears safe and well-tolerated in individuals with recurrent high-grade glioma, supporting further investigation of this approach. doi.org/hbshqk

RP @shwetalm.bsky.social: So excited to share @ivycenter.bsky.social’s publication on early phase clinical trial evaluating safety, feasibility and biological readouts of 5-ALA sonodynamic therapy (SDT) in recurrent high grade glioma patients. www.science…

So excited to share @ivycenter.bsky.social’s publication on early phase clinical trial evaluating safety, feasibility and biological readouts of 5-ALA sonodynamic therapy (SDT) in recurrent high grade glioma patients. www.science.org/doi/10.1126/... @nade…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.